If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

Directorate Change

12 Nov 2018 11:30

RNS Number : 0671H
Cello Health PLC
12 November 2018
 

12 November 2018

 

Cello Health plc

("Cello", the "Company", or the "Group")

 

Directorate Change

 

Cello Health plc (AIM: CLL), the global healthcare focused advisory group, is pleased to announce the appointment of Michele Luzi as Non-Executive Director with immediate effect.

 

Michele is an Advisory Partner of Bain and Company, the global management consultancy, and has served on its global Board. He joined Bain in 1990 and is now reducing his time commitment to the partnership. Since 2010 Michele has served on the Board of Midatech Pharma PLC, a UK Nanotechnology Biotech PLC. Michele is an Italian national.

 

Mark Scott, Chief Executive, commented: "We are delighted to have Michele on board. He brings with him first-hand experience of growing a global professional service business, as well as a wide knowledge of the healthcare sector. His contribution will be very helpful as we seek to expand Cello's global footprint."

 

 

Enquiries:

 

Cello Group

020 7812 8460

Mark Scott, Chief Executive

Mark Bentley, Finance Director

Cenkos Securities

0207 397 8900

Mark Connelly

Harry Hargreaves

 

Appendix

Full name (age)

Michele Luzi (61)

Current directorships / partnerships:

ASHWICK DEVELOPMENTS LIMITED

ASHWICK PROJECTS LIMITED

BAINCOMPANY PARTNERS, L.P.

JUBILEE FILM PARTNERSHIP LLP

MIDATECH PHARMA PLC

PROJECT 99 LIMITED

ST JAMES MEDIA LLP

VIESVI LIMITED

Previous directorships / partnerships (in the last five years):

MIDATECH LTD

RMD TRAFFORD HOUSE 2000 LIMITED

RMD TRAFFORD HOUSE LLP

YELLOW SKY PUBLISHING LIMITED

 

As at today's date, Mr Luzi does not hold any ordinary shares in the capital of the Company.

There are no further disclosures to be made pursuant to Schedule 2(g) of the AIM Rules for Companies in respect of Mr Luzi's appointment.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOALLFLLLLLFLIT
Date   Source Headline
11th Jan 20064:35 pmRNSNotifiable Interest
11th Jan 20067:00 amRNSPre Close Trading Statement
3rd Jan 20063:44 pmRNSHolding(s) in Company
19th Dec 20057:17 amRNSAcquisition
16th Dec 20051:57 pmRNSAdditional Listing
25th Nov 200512:53 pmRNSAcquisition
20th Oct 20058:00 amRNSInvestor Presentation
14th Oct 20058:00 amRNSChange of Adviser
3rd Oct 20057:00 amRNSOMP Services
27th Sep 20057:02 amRNSInterim Results
2nd Sep 200511:41 amRNSNotice of Results
1st Aug 20057:00 amRNSAcquisition
18th Jul 20057:00 amRNSAcquisition
14th Jul 20059:14 amRNSHolding(s) in Company
11th Jul 20057:00 amRNSPre Close Trading Statement
4th Jul 20055:44 pmRNSHolding(s) in Company
1st Jul 20057:00 amRNSAcquisition
7th Jun 20052:46 pmRNSDirector Share Option Award
6th Jun 20054:43 pmRNSAcquisition Agreement
23rd May 200512:30 pmRNSAGM Statement
4th May 20058:41 amRNSBoard Appointment
25th Apr 20057:00 amRNSBoard Appointment
14th Mar 20057:01 amRNSFinal Results
10th Mar 20054:18 pmRNSHolding(s) in Company
1st Feb 200512:00 pmRNSBoard Appointment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.